Cancer Microenvironment

, Volume 7, Issue 3, pp 153–160 | Cite as

Crosstalk between CTC, Immune System and Hypoxic Tumor Microenvironment

  • Muhammad Zaeem Noman
  • Yosra Messai
  • Jane Muret
  • Meriem Hasmim
  • Salem Chouaib
Original Paper

Abstract

Accumulating evidence indicate that the behavior of tumorigenic cells is highly influenced by their microenvironment. In this regard, microenvironmental hypoxia plays a determinant role in the emergence of CTC (circulating tumor cells) and CSC (cancer stem cells). CTCs are believed to be indicators of residual disease and thus pose an increased risk of metastasis. In spite of being rare and exposed to immune attack, these cells are capable to escape the immune system of the host. Although CTC play a pivotal role in the metastatic cascade and their prognostic impact has been repeatedly demonstrated, little is known about their escape mechanisms to immune system of the host. Therefore a better knowledge of the immunogenicity of these cells and their cross talk with immune killer cells as well as with tumor microenvironment may represent an exciting new immunotherapy opportunity. In this chapter, we will discuss how hypoxia is involved in the regulation of tumor progression and induction of EMT and cancer stem cell like features. We will also illustrate the relationship between hypoxia and CTC and review how CTC interact with the cells of immune system (both innate and adaptive) in terms of their survival and EMT phenotype. We will attempt to outline how hypoxic stress may confer resistance to CTC by giving them EMT and CSC like phenotype. Finally we will discuss whether the inhibition of hypoxic signaling pathways in different compartments of the solid tumor microenvironment will have an impact on CTC number, resistant phenotype and CTC lysis by immune effectors.

Keywords

Hypoxia CTC CSC Immune system 

References

  1. 1.
    Akalay I, Janji B et al (2013) EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction. Autophagy 9(7):1104–1106PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Apostolou P, Toloudi M et al (2012) Cancer stem cells stemness transcription factors expression correlates with breast cancer disease stage. Curr Stem Cell Res Ther 7(6):415–419PubMedCrossRefGoogle Scholar
  3. 3.
    Azuma T, Yao S et al (2008) B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111(7):3635–3643PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Baccelli I, Schneeweiss A et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544PubMedCrossRefGoogle Scholar
  5. 5.
    Blank C, Gajewski TF et al (2005) Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54(4):307–314PubMedCrossRefGoogle Scholar
  6. 6.
    Brizel DM, Scully SP et al (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56(5):941–943PubMedGoogle Scholar
  7. 7.
    Derre L, Corvaisier M et al (2006) Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol 177(5):3100–3107PubMedCrossRefGoogle Scholar
  8. 8.
    Dewhirst MW, Cao Y et al (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8(6):425–437PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Driemel, C., H. Kremling, et al. (2013). “Context-dependent adaption of EpCAM expression in early systemic esophageal cancer” Oncogene.Google Scholar
  10. 10.
    Eliane JP, Repollet M et al (2008) Monitoring serial changes in circulating human breast cancer cells in murine xenograft models. Cancer Res 68(14):5529–5532PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Green TL, Cruse JM et al (2013) Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. Exp Mol Pathol 95(2):174–179PubMedCrossRefGoogle Scholar
  12. 12.
    Green TL, Santos MF et al (2014) Toll-like receptor (TLR) expression of immune system cells from metastatic breast cancer patients with circulating tumor cells. Exp Mol Pathol 97(1):44–48PubMedCrossRefGoogle Scholar
  13. 13.
    Gruber I, Landenberger N et al (2013) Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer. Anticancer Res 33(5):2233–2238PubMedGoogle Scholar
  14. 14.
    Hamai A, Benlalam H et al (2010) Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens 75(1):1–8PubMedCrossRefGoogle Scholar
  15. 15.
    Harris AL (2002) Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38–47PubMedCrossRefGoogle Scholar
  16. 16.
    Hasmim M, Noman MZ et al (2013) Cutting edge: Hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-beta1. J Immunol 191(12):5802–5806PubMedCrossRefGoogle Scholar
  17. 17.
    Hoffmann AC, Warnecke-Eberz U et al (2007) Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers. J Surg Oncol 95(1):51–54PubMedCrossRefGoogle Scholar
  18. 18.
    Kallergi G, Markomanolaki H et al (2009) Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 11(6):R84PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Kallergi G, Papadaki MA et al (2011) Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 13(3):R59PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Keith B, Simon MC (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129(3):465–472PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Konishi J, Yamazaki K et al (2004) B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10(15):5094–5100PubMedCrossRefGoogle Scholar
  22. 22.
    Kudo-Saito C, Shirako H et al (2009) Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15(3):195–206PubMedCrossRefGoogle Scholar
  23. 23.
    Lau KW, Tian YM et al (2007) Target gene selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNA-binding mechanisms. Br J Cancer 96(8):1284–1292PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Li Z, Bao S et al (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15(6):501–513PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Liu S, Li N et al (2013) "Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells.". Gastroenterology 144(5):1031–1041PubMedCrossRefGoogle Scholar
  26. 26.
    Makino Y, Uenishi R et al (2007) Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1): a negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells. J Biol Chem 282(19):14073–14082PubMedCrossRefGoogle Scholar
  27. 27.
    Malmberg KJ, Levitsky V et al (2002) IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 110(10):1515–1523PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Marincola FM, Jaffee EM et al (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273PubMedCrossRefGoogle Scholar
  29. 29.
    Medema JP, de Jong J et al (2001) Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 98(20):11515–11520PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Mehlen P, Puisieux A (2006) Metastasis: a question of life or death. Nat Rev Cancer 6(6):449–458PubMedCrossRefGoogle Scholar
  31. 31.
    Noman MZ, Messai Y et al (2011) Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit Rev Immunol 31(5):357–377PubMedCrossRefGoogle Scholar
  32. 32.
    Pardal R, Clarke MF et al (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3(12):895–902PubMedCrossRefGoogle Scholar
  33. 33.
    Raimondi C, Gradilone A et al (2011) Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 130(2):449–455PubMedCrossRefGoogle Scholar
  34. 34.
    Reya T, Morrison SJ et al (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111PubMedCrossRefGoogle Scholar
  35. 35.
    Salceda S, Caro J (1997) Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272(36):22642–22647PubMedCrossRefGoogle Scholar
  36. 36.
    Schulze K, Gasch C et al (2013) Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 133(9):2165–2171PubMedCrossRefGoogle Scholar
  37. 37.
    Semenza GL (2009) HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des 15(33):3839–3843PubMedCrossRefGoogle Scholar
  38. 38.
    Smith HA, Kang Y (2013) The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) 91(4):411–429CrossRefGoogle Scholar
  39. 39.
    Steinert G, Scholch S et al (2014) Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res 74(6):1694–1704PubMedCrossRefGoogle Scholar
  40. 40.
    Theodoropoulos PA, Polioudaki H et al (2010) Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 288(1):99–106PubMedCrossRefGoogle Scholar
  41. 41.
    Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454PubMedCrossRefGoogle Scholar
  42. 42.
    Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2):131–142PubMedCrossRefGoogle Scholar
  43. 43.
    Tinhofer I, Saki M et al (2014) Cancer stem cell characteristics of circulating tumor cells. Int J Radiat Biol 1–6Google Scholar
  44. 44.
    Vander Griend DJ, Karthaus WL et al (2008) The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68(23):9703–9711PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Vegran F, Boidot R (2013) Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and −6 in cancer cells. Oncoimmunology 2(11):e26328PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Wang GL, Jiang BH et al (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92(12):5510–5514PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Wang Y, Liu Y et al (2011) Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 8(4):399–411PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Wohlfart S, Sebinger D et al (2004) FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma. Am J Pathol 164(3):1081–1089PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Yie SM, Luo B et al (2006) Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA. Clin Exp Metastasis 23(5–6):279–289PubMedCrossRefGoogle Scholar
  50. 50.
    Yu M, Bardia A et al (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339(6119):580–584PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Muhammad Zaeem Noman
    • 1
  • Yosra Messai
    • 1
  • Jane Muret
    • 1
  • Meriem Hasmim
    • 1
  • Salem Chouaib
    • 1
  1. 1.INSERM U753Gustave Roussy Cancer campusVillejuifFrance

Personalised recommendations